NEW YORK (GenomeWeb News) – UK-based contract research and synthetic DNA firm SpheriTech said today that it has received an investment of an undisclosed sum from an anonymous angel investor.

The company is using the funds, which it said is in the six-figure range, to hire additional staff and to attract other investors and win government research grants or loans.

"For a company like ours to get off the ground, it's absolutely essential to secure government finance," SpheriTech CEO and Founder Don Wellings said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.